BioGaia BIOG B
This picture changes. Follow BioGaia free — email when the signal or risk changes + a Sunday weekly brief.
Follow BioGaia freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 18 Jul 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Hold; consider adding 10–20% on an earnings dip if outlook holds.
Pros: Net-cash balance sheet, high profitability, clear growth momentum.
- Unknowns: Cost base and margin trajectory as in-house distribution scales.
- Key checkpoint: Q1 earnings to validate whether Q4 momentum persists.
- Conclusion: Hold until earnings improve visibility on growth vs. margin trade-offs.
Market sentiment
7/10
→
Trend: Stable
Overall news/analyst sentiment is positive after a strong Q4, with debate focused on margin pressure and ROI on higher investments. Shorting activity is mentioned as a potential near-term trading factor.
Risk assessment
3/10
Dilution:
Low
Net cash and positive operating cash flow
Jurisdiction:
Low
Sweden and established markets dominate exposure
Execution:
Medium
Shift to direct distribution requires strong execution
Recent changes
- A new Q1 2026 report appears in recent news: net sales 372.6 MSEK (+2% reported, +15% ex FX) and EBIT 101.2 MSEK (~27% margin) with stronger cash flow.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
BioGaia is a Swedish healthcare company developing and selling clinically documented probiotics, primarily based on L. reuteri. The company is profitable with strong margins and a very strong net-cash balance sheet. The strategy focuses on growth through increased in-house distribution and marketing investments.
Sector:
Probiotics and microbiome health
Type:
Biotech
Next report
22 Oct 2026
Q3
Catalysts
22 Oct 2026
Q3 2026 report
High
Q4 2026
Asia launches/approvals (H2 2026)
Medium
Horizon:
Bull case
Sustained organic growth and margin expansion, especially in Adult Health, could lift earnings expectations if momentum continues through H2 2026.
Bear case
Weaker APAC performance and FX headwinds, plus execution/cost risk from scaling own distribution, could increase volatility and pressure reported margins.
Signal rationale (informational)
Pros: Net-cash balance sheet, high profitability, clear growth momentum.
- Unknowns: Cost base and margin trajectory as in-house distribution scales.
- Key checkpoint: Q1 earnings to validate whether Q4 momentum persists.
- Conclusion: Hold until earnings improve visibility on growth vs. margin trade-offs.
Recent news
- BioGaia released its Q2 2026 interim report (17 July): net sales SEK 440.9m (~+12% FX-adjusted), EBIT SEK 132.1m and adjusted EBIT SEK 143.4m (33% margin), with particularly strong growth in Adult Health (+23% FX-adjusted) and EMEA (+21% FX-adjusted); cash flow was negative mainly due to dividend payments and cash amounted to SEK 446.3m, while the share rose notably on the report day.
Price & valuation
Last close
SEK 112
1 week
-0.1 %
3 months
-14.4 %
12 months
+19.8 %
From 52w high
-16.8 %
From 52w low
+19.8 %
Exchange
Stockholm
Type
Biotech
Sector
Probiotics and microbiome health
This picture changes. Follow BioGaia free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.